stockrowAmylyx Pharmaceuticals, Inc. (AMLX) vs Prestige Consumer Healthcare Inc. (PBH)
- Amylyx Pharmaceuticals, Inc. AMLX 28.62 +3.62%
- Prestige Consumer Healthcare Inc. PBH 43.39 −2.10%
Amylyx Pharmaceuticals, Inc. and Prestige Consumer Healthcare Inc. are both Drug Manufacturers Specialty & Generic companies. Amylyx Pharmaceuticals, Inc. is the larger, with a market value of $3.5B against $2.1B — 1.7× the size. Amylyx Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Prestige Consumer Healthcare Inc. trades at 13.7×. Prestige Consumer Healthcare Inc. grew revenue faster over the last twelve months: 5.10% against −77.1%. Prestige Consumer Healthcare Inc. has the higher net margin (13.3% vs 0.00%) and the higher return on invested capital (9.59% vs 0.00%). Across the 17 metrics below, Prestige Consumer Healthcare Inc. leads on 14 and Amylyx Pharmaceuticals, Inc. on 3.
Valuation
Profitability
| Metric | AMLX | PBH | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | (42.65%) | 52.47% | 53.51% |
| Operating margin | 0.00% | 24.95% | 0.00% |
| Net margin | 0.00% | 13.29% | (2.45%) |
| Free cash flow margin | 0.00% | 18.35% | 0.00% |
| Return on equity | (74.73%) | 8.23% | (0.80%) |
| Return on assets | (66.25%) | 3.80% | (1.67%) |
| Return on invested capital | 0.00% | 9.59% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack